Head-to-head evidence
CTX310 vs EDP167
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: ANGPTL3 · full Atherosclerotic Cardiovascular Disease pipeline
CTX310
Developed by CRISPR Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT07491172 (registry estimate)
EDP167
Developed by Eddingpharm (Zhuhai) Co., Ltd.
NCT07412080 · Phase 1 · completed
Participants were randomized to active drug or placebo with full blinding maintained, but the primary endpoint is safety and tolerability rather than a lipid or cardiovascular outcome, and results are not yet posted, so its eventual finding is unknown.
Next expected readout: November 2027 · NCT07799129 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CTX310's landscape · EDP167's landscape